P3 Health Partners (NASDAQ:PIII) Issues Earnings Results

P3 Health Partners (NASDAQ:PIIIGet Free Report) issued its quarterly earnings data on Monday. The company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.26, FiscalAI reports. The company had revenue of $386.38 million for the quarter, compared to analysts’ expectations of $377.80 million.

Here are the key takeaways from P3 Health Partners’ conference call:

  • Adjusted EBITDA reached $54 million in Q2, versus a $17 million loss a year earlier, bringing first-half EBITDA to $80 million. However, approximately $45 million of Q2 EBITDA came from favorable payer settlements and prior-year development, with underlying Q2 EBITDA of about $9 million.
  • The company raised its 2026 adjusted EBITDA outlook to $80 million–$110 million, with a $95 million midpoint, citing improved payer economics, medical-cost performance, and greater earnings predictability.
  • First-half Medicare Advantage medical-cost trend was 1.8% below the 2025 baseline, supported by utilization management, payment integrity, care management, quality execution, and expanded AI-enabled point-of-care tools reaching more than 65,000 members.
  • At-risk membership declined to approximately 105,000 from 116,000 a year earlier following portfolio exits, while cash and equivalents stood at only $21 million at quarter-end. Management also expects normal seasonal medical-expense pressure in the second half.
  • The Nebraska market is progressing as planned, with P3 providing services in 2027 before assuming full risk in 2028, reflecting management’s deliberate approach to geographic expansion and risk exposure.

P3 Health Partners Stock Performance

PIII stock opened at $12.83 on Tuesday. P3 Health Partners has a one year low of $1.52 and a one year high of $16.89. The firm has a market cap of $92.89 million, a price-to-earnings ratio of -0.33 and a beta of 1.63. The firm has a 50-day simple moving average of $10.98 and a two-hundred day simple moving average of $6.40.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on PIII shares. UBS Group set a $14.00 target price on P3 Health Partners in a research report on Friday, May 15th. Wall Street Zen upgraded shares of P3 Health Partners to a “hold” rating in a report on Saturday, July 4th. Lake Street Capital reissued a “buy” rating and issued a $14.00 price objective (up from $4.00) on shares of P3 Health Partners in a research report on Friday, May 15th. TD Cowen restated a “hold” rating and issued a $14.00 target price (up from $3.00) on shares of P3 Health Partners in a research note on Friday, May 22nd. Finally, Weiss Ratings raised shares of P3 Health Partners from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, May 28th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $14.00.

Check Out Our Latest Stock Report on P3 Health Partners

About P3 Health Partners

(Get Free Report)

P3 Health Partners is a healthcare technology and services company that delivers data-driven solutions to support health plans in improving quality measures, risk adjustment accuracy and operational efficiency. The company’s platform integrates advanced analytics, reporting capabilities and workflow automation to help clients optimize performance across value-based care programs and regulatory requirements.

The company’s core offerings include quality measurement and reporting for HEDIS, STAR and other performance frameworks, risk adjustment coding and audit services, and population health analytics.

Featured Stories

Earnings History for P3 Health Partners (NASDAQ:PIII)

Receive News & Ratings for P3 Health Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for P3 Health Partners and related companies with MarketBeat.com's FREE daily email newsletter.